1<!DOCTYPE html>

Products & Services Medical Affairs Medical Affairs Excellence

Medical Affairs Resources, Structures & Trends

ID: 5049


2 Info Graphics

21 Data Graphics

118 Metrics

20+ Narratives

Pages/Slides: 40

Published: Pre-2016

Delivery Format: Online PDF Document


License Options:

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.

Buy Now


Non-members: Click here to review a complimentary excerpt from "Medical Affairs Resources, Structures & Trends"

Study Overview

Charged with building and maintaining physician relationships, pharmaceutical Medical Affairs organizations typically oversee several important functions -- including publications, KOL programs, grants and medical education (CME) -- that have been impacted in recent years by a call for increased transparency. As such, forward-looking biopharmaceutical executives are evaluating Medical Affairs operations to ensure it is appropriately structured and resourced to operate effectively in the current environment.

This Best Practices, LLC study explores how U.S. and global biopharmaceutical companies are structuring and managing their Medical Affairs organizations. The study also examines recent trends in budget and staffing resources, key challenges and top success factors for the function. Pharmaceutical, biotech and medical device managers and executives will be able to use this research to determine how their Medical Affairs organizations compare with industry benchmarks.

Key Topics

  • Organizational Structure
  • Reporting Relationship
  • Job Level of Group Leader
  • Geographic Span
  • Budget Allocation by Medical Affairs Function
  • Percent of Budget Allocated for Outsourcing
  • Recent and Anticipated Changes in Resource Levels
  • Impact of Medical Affairs Functions on Company Success
  • Key Success Factors for Medical Affairs
  • Key Challenges for Medical Affairs
  • Appendix

Key Metrics
  • Type of structure (centralization)
  • Medical Affairs group dedication
  • Departmental reporting relationships
  • Job level or Medical Affairs head
  • Geographic span of organization
  • Percentage of spending per Medical Affairs function
  • Directional trends in Medical Affairs funding levels
  • Directional trends in staffing levels
  • Reasons cited for budget/staff increases
  • Reasons cited for budget/staff decreases
  • Relative importance of seven different Medical Affairs functions
  • Reasons cited for increased importance
  • Reasons cited for decreased importance
  • Percentage of budget allocated for outsourcing
  • Percent of companies impacted by FDA Revitalization Act
  • Top three success factors for developing and maintaining effective Medical Afffairs group
  • Top three challenges for developing and maintaining effective Medical Afffairs group

Sample Key Findings

1. Structure: The Medical Affairs organization is most often a centralized, dedicated group with a global geographic span that includes the U.S. Typically, Medical Affairs organizations report to the Executive Team (42 percent) rather than to Marketing or R&D. The head of Medical Affairs holds the job level of vice president or above at a majority of companies (54 percent.)

2. Spending: On average, 37 percent of Medical Affairs spending is allocated for medical/clinical research operations, with the top quartile spending more than 60 percent for the clinical function. Medical Educations takes up about 18 percent of Medical Affairs allocations.


Twenty-six Medical Affairs leaders at 25 pharmaceutical companies participated in this benchmarking research project.

Industries Profiled:
Biotech; Pharmaceutical; Manufacturing; Consumer Products; Diagnostic; Medical Device; Chemical; Health Care

Companies Profiled:
Amgen; Astellas; AstraZeneca Pharmaceuticals; Bayer Schering AG; Bayer; Auxilium; Becton Dickinson; Bristol-Myers Squibb; Cubist Pharmaceuticals; Esteve; Genentech; Johnson & Johnson; Myriad; Novartis; Novo Nordisk; Pfizer; Schering-Plough; Solvay Pharmaceuticals; Vertex Pharmaceuticals; ApoPharma; OctoPlus; Procaps; Savient; SK&F; Werrick

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.